Singapore - English - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - clinical chemistry - the hcg method for the dimension® clinical chemistry system with the heterogeneous immunoassay module is intended to quantitatively measure intact human chorionic gonadotropin in human serum and plasma for the early detection of pregnancy.

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - chorionic gonadotropin - injection - chorionic gonadotropin 10,000 iu/vial

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bsv bioscience malaysia sdn. bhd. - chorionic gonadotrophin -

United States - English - NLM (National Library of Medicine)

organon llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovula

Kenya - English - Pharmacy and Poisons Board

sanzyme (p) ltd c/o surgilinks ltd plot no:13, sagar society, road no:2, banjara - chorionic gonadotrophin - injection - chorionic gonadotrophin 5000 iu - gonadotropins

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

Canada - English - Health Canada

emd serono, a division of emd inc., canada - choriogonadotropin alfa - solution - 250mcg - choriogonadotropin alfa 250mcg - gonadotropins and antigonadotropins

United States - English - NLM (National Library of Medicine)

a-s medication solutions - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.